UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

SLC15A2

Synonyms: FLJ33407, PEPT2

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ	Source	Relative Expression
Brain	Nishimura	`0.0271`
Kidney*	Nishimura	`0.0297`
Liver	Nishimura	`0.000631`
Placenta	Nishimura	`0.00131`
Small Intestine	Nishimura	`0.000804`
Kidney*	Mean across all PMT Samples	`4.617`
Liver	Mean across all PMT Samples	`0.562`

Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate	Km (μM)	Cell System	Reference
5-aminolevulinic acid	227	PEPT2-expressing oocytes	Doring, 1998
Amoxicillin	1040	MDCK-PEPT2	Li, 2006
Bestatin	ND	PEPT2-expressing oocytes	Sala-Rabanal, 2008
Cefaclor	72	MDCK-PEPT2	Li, 2006
Enalapril	ND	PEPT2-expressing oocytes	Li, 2008
Glycylsarcosine	74	HeLa-PEPT2	Ramamoorthy, 1995
Glycylsarcosine	170	HEK293-PEPT2	Terada, 2004
Glycylsarcosine	140	SKPT cells	Knutter, 2009

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022

In Vitro Inhibitors

Inhibitor	Ki (μM)	Substrate used	Cell System	Reference
Amoxicillin	733	Glycylsarcosine	MDCK-PEPT2	Li, 2006
Anserine	180	Glycylsarcosine	HeLa-PEPT2	Geissler, 2010
Carnosine	60	Glycylsarcosine	HeLa-PEPT2	Geissler, 2010
Cefaclor	65	Glycylsarcosine	MDCK-PEPT2	Li, 2006
Cephalexin	98	Glycylsarcosine	CHO-PEPT2	Pinsonneault, 2004
Kyotorphin	5.1	Glycylsarcosine	CHO-PEPT2	Pinsonneault, 2004
Losartan	2.4	Glycylsarcosine	HeLa-PEPT2	Knutter, 2009
Valsartan	110	Glycylsarcosine	HeLa-PEPT2	Knutter, 2009

Clinical Drug-Drug Interactions

No drug-drug interaction information.